Rhode Island State

Connecticut State

Columbus, OH

Summary: Researchers reversed Alzheimer’s symptoms in mice using a synthetic peptide, PHDP5, that targets brain function. The study shows that PHDP5 can cross the blood-brain barrier and restore memory by improving synaptic function. The treatment could delay cognitive decline if administered early. This breakthrough paves the way for new...

Synthetic Peptide Reverses Alzheimer’s Symptoms

The US Food and Drug Administration (FDA) approved a drug made by Eli Lilly on Tuesday that is designed to treat the early symptoms of Alzheimer's disease. The drug known as Kisunla should be used by "patients with mild cognitive impairment or mild dementia stage of disease," the FDA said in a statement announcing its decision to approve the drug.

FDA Approves Eli Lilly's New Alzheimer's Drug For Early Disease Symptoms

The FDA has approved a new Alzheimer’s drug called Kisunla from Eli Lilly, which can modestly slow the progression of the disease in patients with mild or early dementia caused by Alzheimer’s. This marks the second drug to convincingly show a delay in cognitive decline in Alzheimer’s patients,...

Second Alzheimer’s drug approved by FDA

The early signs of dementia in women include memory loss and confusion. Dementia is a collective term that describes various symptoms of cognitive decline, such as forgetfulness, confusion, and changes in behavior. It is not a specific disease but a group of conditions characterized by impairment of at least two brain functions, such as memory loss and judgment.

Early signs of dementia in women

The FDA has authorized an Investigational New Drug (IND) application for Synaptogenix, Inc.’s Bryostatin-1 as a potential treatment for multiple sclerosis (MS). The fully-funded, open-label clinical trial will be held and managed at Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis. The study will utilize 7T MRI technology to identify biomarkers for evaluating Bryostatin-1's impact on the brain.

Clinical Trial for Multiple Sclerosis Treatment to Use 7T MRI

The U.S. Food and Drug Administration (FDA) has given Iregene Therapeutics the green light to launch a clinical trial testing its cell therapy NouvNeu001, being developed for moderate to advanced Parkinson’s disease. According to the company, this marks a significant milestone, with NouvNeu001 becoming the world’s first chemically induced...

FDA OKs Parkinson’s clinical trial to test NouvNeu001 cell therapy

Fibromyalgia and sleep apnea both disrupt nighttime sleep. Chronic pain from fibromyalgia can affect your ability to fall or stay asleep. Sleep apnea can increase symptoms of fibromyalgia. Are you finding yourself waking up frequently in the night and having a hard time getting up in the morning? Is fatigue...

The Link Between Fibromyalgia and Sleep Apnea

TIME

The new research is early, but it's a hopeful advance for patients with the neurological condition.

A Potential Parkinson's Treatment Has Promising Results

TheConversationAU

What’s the difference? is a new editorial product that explains the similarities and differences between commonly confused health and medical terms, and why they matter. Changes in thinking and memory as we age can occur for a variety of reasons. These changes are not always cause for concern. But when they begin to disrupt daily life, it could indicate the first signs of dementia.

What’s the difference between Alzheimer’s and dementia?

The Food and Drug Administration (FDA) granted approval to Eli Lilly for their Alzheimer's drug donanemab. This decision marks a notable expansion of the treatment options available for individuals suffering from this debilitating disease in the United States. Eli Lilly's Alzheimer's Drug Donanemab Approved by FDA. Eli Lilly has finally...

FDA Approves Eli Lilly's Alzheimer’s Drug Donanemab, Expanding US Treatment Options

The U.S. has entered the “fourth wave” of the overdose epidemic, characterized by skyrocketing use of stimulants like methamphetamine. A new study found that a duo of drugs is effective at curbing methamphetamine-positive drug tests by 27% compared to a placebo. “These findings have important implications for pharmacological...

No FDA-Approved Meth Treatments Exist, But New Study Offers Hope

This announcement follows an earlier FDA decision to grant approval to the company’s tissue-based comprehensive genomic profiling test FoundationOne CDx for the same therapy and indication in August 2023. The FDA has approved the liquid biopsy test FoundationOneLiquid CDx for use as a companion diagnostic in identifying patients with...

FDA approves FoundationOneLiquid CDx for niraparib/abiraterone in mCRPC

Newark, NJ

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

Morristown Minute

NEWARK, N.J. – Eight individuals associated with the "793 Bloods" street gang, a subset of the national Bloods gang, have been charged for their roles in a Newark-based drug trafficking organization, U.S. Attorney Philip R. Sellinger announced.

Eight '793 Bloods' Gang Members Charged in Newark Drug Network

ScienceAlert


Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for  Parkinson's disease from cell-to-cell in the brain.
Promisingly, an FDA-approved  cancer drug that targets another protein called Lag3 – which interacts with Aplp1 – blocks the spread in mice, suggesting a potential therapy may already exist.



					
			

In a new paper, an international team of scientists describes how the two proteins work together to help harmful alpha-synuclein protein clumps get into brain cells.
"Now that we know how Aplp1 and Lag3 interact, we have a new way of understanding how alpha-synuclein contributes to...

Parkinson's Discovery Suggests We May Already Have an FDA-Approved Treatment

Virginia State

Writers represent independent, third-party users who have joined our contributor program and self-verified their accounts. Writers are expected, like all users, to adhere to our Community Standards.

writer

Cheryl E Preston

Virginia fans of The Bold and the Beautiful are pretty much unified in their expectations of what will happen between Thomas Forrester (Matthew Atkinson) and Paris Buckingham (Diamond White), who recently announced their engagement.

The Bold and the Beautiful fans believe Thomas will dump Paris for Hope

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's drug donanemab (Kisunla) for the treatment of early Alzheimer's disease, including mild cognitive impairment or mild dementia. Donanemab is a monoclonal antibody that targets and clears beta-amyloid protein in the brain. It is the second drug approved by the...

FDA approves donanemab for Alzheimer's disease

New Jersey State

Clifton, NJ

Newark, NJ – Evangelos Megariotis, a 72-year-old orthopedic surgeon from Clifton, admitted to multiple counts of unlawfully prescribing pain medications to his patients. U.S. Attorney Philip R. Sellinger announced the guilty plea today.

Surgeon Guilty of Illegal Narcotic Prescriptions, Faces 20 Years

The Independent

A family history of Alzheimer’s disease on the mother’s side might increase the chances of someone developing the condition, new research suggests.Whether a person inherits risk of Alzheimer’s from their mother or father influences the danger of changes in the brain that lead to disease, according to the new study.After evaluating 4,400 adults aged 65 to 85 who had memory loss and trouble solving problems, the researchers found those with a history of Alzheimer’s on either their mother’s side, or both parents’ sides, had increased proteins (amyloids) linked to Alzheimer’s in the brain.The findings suggest that considering sex-specific parental history...

Alzheimer’s disease on mother’s side linked to ‘increased risk’ of the condition

Georgia State

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

Coffee County, GA

Douglas, GA

Daily Coffee Press

A 49-year-old woman from Douglas was recently arrested for allegedly submitting a life insurance policy for her ex-husband without his knowledge. According to a Coffee County Sheriff’s Office incident report, detectives met with a man on May 7 at the Coffee County Law Enforcement Center concerning a reported case of insurance fraud.

Georgia woman charged for allegedly filing life insurance policy application on ex-husband

NewsBreak

New FDA approved Alzheimer's treatment targets early stage patients

\"For 30 years we didn't have anything but medications for those symptoms of this disease, and now there are medications that may give these families more...

"For 30 years we didn't have anything but medications for those symptoms of this disease, and now there are medications that may give these families more...

New FDA approved Alzheimer's treatment targets early stage patients

Comments / 0